Tabula Rasa Healthcare Inc. (NASDAQ:TRHC)‘s stock had its “buy” rating reaffirmed by analysts at Stifel Nicolaus in a research report issued to clients and investors on Friday. They currently have a $16.00 target price on the stock. Stifel Nicolaus’ price target suggests a potential upside of 6.31% from the company’s previous close.
Several other equities research analysts have also recently issued reports on the stock. Chardan Capital assumed coverage on shares of Tabula Rasa Healthcare in a research report on Monday, July 10th. They set a “buy” rating and a $19.50 price objective on the stock. UBS AG reiterated a “buy” rating and set a $17.00 price objective (down previously from $18.00) on shares of Tabula Rasa Healthcare in a research report on Thursday, May 25th. Finally, Zacks Investment Research upgraded shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $17.25.
Tabula Rasa Healthcare (TRHC) opened at 15.05 on Friday. The firm has a 50-day moving average of $13.64 and a 200-day moving average of $13.91. The stock’s market cap is $259.13 million. Tabula Rasa Healthcare has a 1-year low of $10.39 and a 1-year high of $16.85.
Tabula Rasa Healthcare (NASDAQ:TRHC) last released its quarterly earnings data on Monday, May 1st. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.02. The firm had revenue of $27.70 million for the quarter, compared to analysts’ expectations of $26 million. The company’s revenue was up 37.1% on a year-over-year basis. Analysts expect that Tabula Rasa Healthcare will post $0.41 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/07/18/tabula-rasa-healthcare-inc-nasdaqtrhc-rating-reiterated-by-stifel-nicolaus.html.
In related news, insider Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $14.02, for a total value of $112,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gordon Tunstall sold 22,759 shares of the firm’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $13.76, for a total transaction of $313,163.84. Following the completion of the transaction, the director now directly owns 5,565 shares of the company’s stock, valued at $76,574.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,759 shares of company stock valued at $520,844. 45.80% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in Tabula Rasa Healthcare by 37.2% in the first quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock worth $10,544,000 after buying an additional 212,164 shares during the period. Hood River Capital Management LLC raised its position in Tabula Rasa Healthcare by 30.1% in the first quarter. Hood River Capital Management LLC now owns 767,501 shares of the company’s stock worth $10,346,000 after buying an additional 177,774 shares during the period. Russell Investments Group Ltd. acquired a new position in Tabula Rasa Healthcare during the fourth quarter worth $875,000. Bank of New York Mellon Corp acquired a new position in Tabula Rasa Healthcare during the first quarter worth $178,000. Finally, TIAA CREF Investment Management LLC raised its position in Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock worth $110,000 after buying an additional 4,232 shares during the period. 24.93% of the stock is owned by hedge funds and other institutional investors.
About Tabula Rasa Healthcare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.